Monomethyl Fumarate
Relapsing-Remitting Multiple Sclerosis
Explore 71 assets in Relapsing-Remitting Multiple Sclerosis →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Banner Life Sciences LLC
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05978531CT.gov Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice | — | Terminated | — | — | — |
NCT04925778CT.gov Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate | — | Withdrawn | — | — | — |
NCT05181215CT.gov Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects | — | Completed | — | — | — |
NCT04570670CT.gov Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsing-Remitting Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Monomethyl Fumarate (this asset) | Banner Life Sciences LLC | P1 | CCC · 52 |
| Glatiramer | University Hospital, Montpellier | P4 | BBB |
| Natalizumab | Biogen | P4 | BBB |
| Fingolimod | TG Therapeutics, Inc. | P4 | BBB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Biogen | P4 | BBB |
| Cladribine | Uppsala University | P4 | BBB |
| Ocrelizumab | Biocad | P4 | BBB |
| 2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER | University Hospital, Montpellier | P4 | BBB |
| Peginterferon Beta-1A | Biogen | P4 | BBB |
+42 more in the Relapsing-Remitting Multiple Sclerosis cohort
Other indications for Monomethyl Fumarate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Multiple Sclerosis | — | P3 | BB · 64 |
| Schizophrenia | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Monomethyl Fumarate in Relapsing-Remitting Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/monomethyl-fumarate-relapsing-remitting-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →